Last reviewed · How we verify

Symbicort® forte Turbohaler®

University Hospital, Antwerp · FDA-approved active Small molecule

Symbicort® forte Turbohaler® is a Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Small molecule drug developed by University Hospital, Antwerp. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Symbicort combines a long-acting beta-2 agonist (formoterol) and an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation.

Symbicort combines a long-acting beta-2 agonist (formoterol) and an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameSymbicort® forte Turbohaler®
SponsorUniversity Hospital, Antwerp
Drug classInhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)
TargetGlucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhaseFDA-approved

Mechanism of action

Budesonide is a corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 agonist that activates beta-2 adrenergic receptors on bronchial smooth muscle, causing bronchodilation and sustained airway opening. The combination provides both anti-inflammatory and bronchodilatory effects for maintenance asthma and COPD control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Symbicort® forte Turbohaler®

What is Symbicort® forte Turbohaler®?

Symbicort® forte Turbohaler® is a Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) drug developed by University Hospital, Antwerp, indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does Symbicort® forte Turbohaler® work?

Symbicort combines a long-acting beta-2 agonist (formoterol) and an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation.

What is Symbicort® forte Turbohaler® used for?

Symbicort® forte Turbohaler® is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes Symbicort® forte Turbohaler®?

Symbicort® forte Turbohaler® is developed and marketed by University Hospital, Antwerp (see full University Hospital, Antwerp pipeline at /company/university-hospital-antwerp).

What drug class is Symbicort® forte Turbohaler® in?

Symbicort® forte Turbohaler® belongs to the Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) class. See all Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) drugs at /class/inhaled-corticosteroid-long-acting-beta-2-agonist-combination-ics-laba.

What development phase is Symbicort® forte Turbohaler® in?

Symbicort® forte Turbohaler® is FDA-approved (marketed).

What are the side effects of Symbicort® forte Turbohaler®?

Common side effects of Symbicort® forte Turbohaler® include Tremor, Headache, Palpitations, Oral candidiasis, Nervousness/anxiety.

What does Symbicort® forte Turbohaler® target?

Symbicort® forte Turbohaler® targets Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol) and is a Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA).

Related